NovMetaPharma Co., Ltd.   Report issue

For profit Phase 2
Founded: Seoul Korea, Republic of (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2018
NCT03560271
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

NovMetaPharma Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

cyclo-z (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1